Table 1.
Summary statistics of patients excluded/included in the analysis
| Excluded | Included | |
|---|---|---|
| N = 164 | N = 242 | |
| Age | 61.1 (17.6) | 58.0 (19.9) |
| Age (grouped) | ||
| 18–29 years | 5 (3.05%) | 15 (6.20%) |
| 30–39 years | 21 (12.8%) | 44 (18.2%) |
| 40–49 years | 21 (12.8%) | 38 (15.7%) |
| 50–64 years | 38 (23.2%) | 44 (18.2%) |
| 65–74 years | 34 (20.7%) | 38 (15.7%) |
| 75–84 years | 31 (18.9%) | 35 (14.5%) |
| > 85 years | 14 (8.54%) | 28 (11.6%) |
| Sex | ||
| Man | 112 (68.3%) | 144 (59.5%) |
| Woman | 52 (31.7%) | 98 (40.5%) |
| Vaccination | ||
| No | 73 (44.5%) | 117 (48.3%) |
| Yes | 91 (55.5%) | 125 (51.7%) |
| Vaccination status | ||
| Not complete | 83 (50.6%) | 135 (55.8%) |
| Complete | 81 (49.4%) | 107 (44.2%) |
| Vaccination type | ||
| No | 73 (44.5%) | 117 (48.3%) |
| Adenovirus-based | 28 (17.1%) | 29 (12.0%) |
| mRNA | 63 (38.4%) | 96 (39.7%) |
| First vaccination | ||
| Pfizzer | 54 (59.3%) | 85 (68.0%) |
| Moderna | 9 (9.89%) | 11 (8.80%) |
| Janssen | 18 (19.8%) | 18 (14.4%) |
| Astrazeneca | 10 (11.0%) | 11 (8.80%) |
| Days from exposure* to survey date (median [IQR]) | – | 15 [4–51] |
*For cases where only an interval of exposure is available, the middle point of this interval is taken as exposure date